Quite a nice list of large partners already. One has to wonder about these large pharma companies and their collaboration with GLGC. What motivates them? What kind of statistical ratio of submitted drugs/milestones (and maybe royalties) could one expect? The ratio is 1/3 for stage one; would it be something like 1/10 for payout of these? One can only guess because there have been no "bingos" yet. Their database is still available for drug evaluation/exploration. No more losing money on the Genomics division - liabilities assumed..... I have some at a dollar.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.